CIRCULOGENE Molecular Diagnostics Laboratory Receives College of American Pathologists (CAP) Accreditation

BIRMINGHAM, Ala.–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;#Accreditationlt;/agt;–CIRCULOGENE,
advancing precision medicine through personalized molecular genetics
testing, announced today that its molecular diagnostics laboratory has
received College of American Pathologists (CAP) accreditation based on a
recent on-site inspection as part of CAP’s Accreditation Programs. The
CAP accreditation – and the Clinical Laboratory Improvement Amendments
(CLIA) certification that CIRCULOGENE achieved in 2015 – are
internationally recognized credentials awarded to laboratories complying
with the most comprehensive, rigorous and scientifically-endorsed
standards of laboratory practice.

“This CAP accreditation milestone is a testament to the high-quality
scientific standards that our laboratory strives for in pursuit of
molecular diagnostics testing excellence and better patient care,” said
CIRCULOGENE Chief Scientific Officer Chen-Hsiung Yeh, Ph.D. “We’ll
continue to advance precision medicine through our highly accurate,
automated and scalable cell-free DNA and RNA technology to help
clinicians fight an increasingly broad range of cancers.”

Bharati Jhaveri, M.D., F.C.A.P., chair of the CAP’s Council on
Accreditation, recognized CIRCULOGENE on its achievement.

“The CAP congratulates CIRCULOGENE on its recent CAP Accreditation,”
said Jhaveri. “CIRCULOGENE demonstrates leadership, innovation and a
passionate commitment to standards of excellence while providing the
highest quality services, ultimately benefiting patients.”

CIRCULOGENE’s proprietary technology platform provides comprehensive
genomic testing services that help oncologists and pathologists select
the right clinical trials and the most effective cancer therapies
available for their patients, as well as monitoring patient responses,
drug resistance, minimal residual disease and relapse. This includes
immunotherapy, targeted therapy, combination therapy and other precision
medicine approaches.

CIRCULOGENE is the only company that provides circulating DNA, RNA and
MSI cancer immunotherapy testing from a single tube of blood. The
laboratory’s industry-leading turnaround time ensures that complete
testing results are available to physicians and their patients within
one week, all from a single 4 mL tube of blood, no matter which test or
how many tests are ordered.

CIRCULOGENE is a Clinical Laboratory Improvement Amendments (CLIA)
certified and College of American Pathologists (CAP) accredited
laboratory and is registered as a verified U.S.
federal contractor
. For more information, visit our website,
connect with us on LinkedIn,
and Twitter,
email us at
or call 855-614-7083. Clinicians interested in ordering tests may visit
the Contact
page on CIRCULOGENE’s website.


Headquartered in Birmingham, Ala., CIRCULOGENE is an innovative
molecular diagnostics company founded and operated by a team of
experienced industry executives and skilled molecular diagnostics
scientists. Applying its proprietary laboratory developed test for
cfDNA, cfRNA and MSI liquid biopsies, CIRCULOGENE has developed a
next-generation sequencing (NGS) method to provide full genomic load
analysis from one standard tube of blood in one week, enabling more
accurate data to help clinicians and their patients choose targeted
therapies, monitor efficacy and monitor for recurrence. One Tube, One
Week, Complete Results. Somatic + Germline; Blood + Tissue + Buccal; DNA
+ RNA + Immunotherapy. For more information, visit
or call 855-614-7083.

About the College of American Pathologists

As the world’s largest organization of board-certified pathologists
and leading provider of laboratory accreditation and proficiency testing
programs, the College of American Pathologists (CAP) serves patients,
pathologists, and the public by fostering and advocating excellence in
the practice of pathology and laboratory medicine worldwide. For more
information, read the
CAP Annual Report


Media Contact
Dan Snyders
MedTech Content Marketing

Company Contact
Scott Rezek

error: Content is protected !!